Relapse after treatment for moderate acute malnutrition: Risk factors and interventions to prevent it

Summary of presentation based on published research

By Heather Stobaugh and Mark Manary

Location: Malawi

What we know: Little is known on post-discharge outcomes of children treated for moderate acute malnutrition (MAM).

What this article adds: A cluster-randomised controlled trial in Southern Malawi assessed whether a package of five health and nutrition interventions helped sustain recovery for one year after MAM treatment. A total of 1,497 children who recovered from MAM at 21 supplementary feeding programme (SFP) study clinics were enrolled. The treatment group received counselling (as per control) and on discharge were given eight weeks of lipid-based nutrient supplement (LNS), albendazole, 14 weeks of zinc supplementation, an insecticide-treated bed net and malaria chemoprophylaxis during the rainy season. Fifty-one per cent sustained recovery for one year. Many children experienced multiple relapses and relapsed cases took longer to recover on admission. Half of all relapses occurred within three months of discharge. There was no significant difference between relapse-free survival curves for the intervention and control groups; linear growth and illness patterns were also similar for both. The strongest predictors of relapse or death after SFP discharge were lower anthropometric measurements during SFP treatment. Findings suggest not all MAM children carry the same risk; programming implications need further examination.

Background

Children with moderate acute malnutrition (MAM) are generally treated with a supplementary food for several weeks in a community-based supplementary feeding programme (SFP) until they are discharged as recovered after achieving an anthropometric threshold. Little is known about post-discharge and longer-term health and nutrition outcomes. This study assessed whether a package of simple and affordable health and nutrition interventions, added after achieving anthropometric criteria for nutritional recovery from MAM, could improve the proportion of children who sustained recovery for one year after treatment. This cohort was also used to explore factors related to sustained recovery, which remains an elusive but important goal in SFPs.

Methods

This study was a cluster-randomised, controlled, clinical effectiveness trial conducted in southern Malawi. Children aged 6-62 months were enrolled from 21 SFPs at the time of recovery from MAM (mid upper arm circumference (MUAC) ≥ 12.5 cm). Upon enrolment the control group received nutrition counselling, which consisted of messages regarding optimal complementary feeding, caregiver recognition of common childhood illnesses and appropriate health-seeking behaviours. The treatment group received the same counselling plus a package of five additional interventions, including: 1) 40 g/d of a lipid-based nutrient supplement (LNS) for eight weeks after SFP discharge; 2) a single dose of deworming medication (albendazole) at SFP discharge; 3) a 14-day course of zinc supplementation starting at the time of SFP discharge; 4) an insecticide-treated bed net at SFP discharge; and 5) sulfadoxine-pyrimethamine for malaria chemoprophylaxis once a month for three months during the rainy season. These interventions have all individually been proven safe, effective and affordable in this context for improving the overall health of children.

Informed consent was obtained from all caregivers. Upon enrolment, anthropometric measurements were taken and information on demographic characteristics, health history and household food insecurity was collected. Children were followed for one year and reassessed at follow-up visits at one, three, six and 12 months post-SFP discharge. Additional monthly visits were scheduled during the height of the rainy season (December through February), when malaria prophylaxis was also provided at the intervention sites. Caregivers were also encouraged to return to the clinic at any time they perceived their child’s health or nutritional status to worsen. The primary outcome was the proportion of children who sustained recovery, which was defined as maintaining a MUAC ≥ 12.5 cm without bipedal oedema at all follow-up visits during the 12 months after initial recovery from MAM.

Relapse-free survival curves were developed with the use of the Kaplan-Meier method and were compared using the log-rank test. A Cox proportional model for a multivariate analysis

---

1 Presentation at the Action Against Hunger Research for Nutrition Conference, Pavillon de L’Eau, 13th November, 2017. A video of the presentation can be found here: https://youtu.be/paxePashlZo
2 Stobaugh HC, Bollinger LB, Adams SE, Crocker AH, Grise JL, Kennedy JA, Thakwalakwa C, Maleta KM, Dietzen DJ, Manary MJ, et al. Effect of a package of health and nutrition services on sustained recovery in children after moderate acute malnutrition and factors related to sustaining recovery: a cluster-randomized trial. Am J Clin Nutr 2017;106(2):657-66. Children were enrolled into SFP at 6-59 months. If a child was 59 months upon SFP enrolment and received treatment for 12 weeks, s/he could be 62 months old at discharge, which was the time of study enrolment; therefore the enrolment criteria for age was 6-62 months old.
Results
A total of 1,497 children recovered from MAM at 21 SFP study clinics and were enrolled in the study. After excluding ten children due to incorrect enrolment criteria, 1,487 children were included in the final analysis, with 718 children at control sites and 769 at 11 intervention sites.

Of the 1,487 children included in the final analysis, 754 (51 per cent) sustained recovery throughout the 12-month follow-up period, whereas 541 (36 per cent) relapsed to MAM; 73 (5 per cent) developed SAM; 15 (1 per cent) died, and 104 (7 per cent) were lost to follow-up. Many children experienced multiple relapses; of those who relapsed to MAM only, 26 per cent, 10 per cent, and 5 per cent of children relapsed 2, 3, and ≥ 4 times, respectively. In addition, of those who developed SAM, 69 per cent of children also relapsed to MAM more than once. Children who relapsed to MAM multiple times required longer treatment for those relapses during the follow-up period than children who relapsed only once (P < 0.001). Furthermore, MUAC dropped significantly in children who relapsed to MAM multiple times compared to children who relapsed only once (P < 0.001). Risk of relapse or death was highest during the period immediately after discharge from an SFP, with approximately 50 per cent of all relapses (to either MAM or SAM) occurring within the first three months of initial recovery from MAM.

Analysis with the use of the Kaplan-Meier method showed no significant difference between relapse-free survival curves for the intervention and control groups (P = 0.380; log-rank test). Secondary outcomes, including linear growth and illness during the 12-month follow-up period, were similar across both groups.

The outcome variable in the Cox regression model, factors that had a protective effect against relapse or death included: having a larger MUAC on SFP admission (P < 0.01); having a larger MUAC on SFP discharge (P < 0.001); and having a higher weight-for-height z-score (WHZ) on discharge (P < 0.01). Children were also less likely to relapse or die if they received RUTF as opposed to ready-to-use supplementary food (RUSF) during treatment (P < 0.05).

Discussion
This study has shown that the provision of a package of basic health and nutrition interventions to children recovering from MAM did not result in a significant increase in the proportion who sustained recovery for one year. Nearly half of all children who successfully recovered from MAM failed to sustain that recovery for one year following SFP treatment. A diversity of poor outcomes was observed among those who failed to sustain recovery. Some children experienced one short, mild episode of MAM and quickly recovered after re-enrolment in an SFP to remain free from MAM or SAM thereafter, while other children repeatedly relapsed with more severe episodes of acute malnutrition that required long treatment without any sustained recovery. These vastly different trajectories highlight the fact that, although children in SFPs are all classified with the same type and severity of malnutrition (i.e. MAM), not all children with MAM are at the same risk of poor short- and long-term outcomes. This result suggests that a uniform approach for treating all children with MAM may not be best for ensuring that all reach sustained recovery.

The strongest predictors of relapse or death after SFP discharge were lower anthropometric measurements during SFP treatment; therefore the severity of malnutrition at admission to feeding programmes is linked to increased risk of mortality and relapse in children after treatment. Likewise, the higher the MUAC and WHZ score on discharge, the more likely the child is to sustain recovery. It is possible that children who present with more severe malnutrition (i.e. lower MUAC) have additional underlying biological deficiencies that take longer to recover than can be identified by simple anthropometric measurements. Children with higher discharge anthropometric measurements may have reached a better overall health status and are more resilient when exposed to new infections that might otherwise precipitate relapse. This does not necessarily translate to the need for longer time receiving supplementary food in an SFP; rather, treatment protocols may need to adapt to go beyond the mere provision of supplementary food.

Conclusion
Children who successfully recover from MAM after receiving treatment in an SFP are likely to relapse during the following year. A package of basic health and nutrition interventions provided at the time of discharge and during the rainy season did not significantly reduce the proportion of children who sustained recovery. Although most SFP protocols provide the same treatment to children with MAM regardless of the anthropometric measure, our results suggest that treatment and follow-up procedures may benefit from individualisation. Our findings also suggest a potential benefit of treating high-risk children with MAM to higher anthropometric targets to reduce relapse and mortality after discharge. However, this treatment would certainly increase the immediate cost (as well as having long-term cost savings), which is an essential factor to consider before any programmatic change.